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Abstract
Purpose To compare the influence of Cimicifuga racemosa extract (CR, Ze 450) and menopausal hormone therapy (MHT) 
on metabolic parameters and body weight in symptomatic menopausal women.
Methods In this monocentric retrospective cohort study, women over 40 years old with a first consultation between 2009 
and 2016 were screened. Included in the final analysis were women treated with either MHT or CR and having at least one 
follow-up consultation. Metabolic serum parameters (lipids, glucose, insulin, and HOMA-IR), body weight, and menopausal 
symptoms [Menopause Rating Scale (MRS)-II] were the main outcome measures. Statistical analysis by uni- and multi-
variable linear mixed-effects regression models assuming a linear effect of time.
Results 174 women were included in the final analysis (CR n = 32, MHT n = 142). There was no difference between the 
groups regarding baseline characteristics (age, BMI, serum metabolic parameters, hormones, and blood pressure) and total 
MRS-II score, while reproductive stage differed significantly with more postmenopausal women treated with CR (83%) 
than MHT (55%) (p = 0.038). Median follow-up time was 12 months. In both groups, metabolic serum parameters and body 
weight did not change over the follow-up period, while total and MRS-II subscores improved.
Conclusion Menopausal symptoms improved significantly in both groups (MHT and CR), while serum metabolic parameters 
and body weight did not change in MHT- or CR-treated women.
Keywords Black cohosh · Cimicifuga racemosa · Menopause · Body weight · HOMA index · Menopausal hormone therapy
Introduction
The menopausal transition and ageing are accompanied 
by body weight increase of about 0.5 kg annually [1–3]. 
Weight gain, especially during menopause, has been signifi-
cantly associated with increased risk of several diseases [2]. 
Furthermore, body composition changes with visceral fat 
depots increasing and lean body mass decreasing [4] often 
accompanied by adverse changes in metabolic parameters 
[5]. Menopausal hormone therapy (MHT) is usually indi-
cated for menopausal symptom relief, but also has a positive 
impact on body weight, body composition, and metabolic 
parameters [6–8].
Black cohosh (Cimicifuga racemosa, CR) is an alterna-
tive treatment for menopausal hot flushes [9, 10]. Its pre-
cise mechanism of action is controversial. For hot flush 
reduction, CR is thought to modulate the neurotransmitter 
signaling pathways in the brain and not to exert estrogenic 
effects [11–13]. In vitro, the Black cohosh dry extract Ze 450 
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[(DER 4.5–8.5:1), extraction solvent ethanol 60% (V/V)] 
has been shown to dose-dependently activate AMP-activated 
protein kinase (AMPK), an activity regulator of different key 
enzymes involved in lipid synthesis (HMG-CoA reductase 
and acetyl-CoA carboxylase), and some glucose transport-
ers (Glut 1/4) [14]. Herein, AMPK activation was more 
pronounced with Ze 450 than metformin treatment. These 
findings were confirmed in ob/ob mice showing a significant 
reduction of water intake and a normalization of the glucose 
and insulin response to a glucose challenge test [14]. Thus, 
Ze 450 may improve metabolic control via improving insulin 
receptor sensitivity. The aim of this monocentric retrospec-
tive study was to compare the impact of the Black cohosh 
dry extract Ze 450 versus MHT on body weight and meta-
bolic parameters, such as serum lipids, glucose, insulin, and 
HOMA-IR in symptomatic menopausal women.
Methods
Study design
CIMBOLIC is an investigator-initiated monocentric retro-
spective observational study. Coded health-related data of all 
patients above age 40 presenting for first-time consultation 
at the Menopause Centre of the Department of Obstetrics 
and Gynecology, Inselspital Bern, between 01.04.2009 and 
31.12.2016 were abstracted from medical records. Routine 
assessment comprised personal and family history includ-
ing reproductive age [15], medication, lifestyle factors 
(smoking, alcohol), questionnaire Menopause Rating Scale 
(MRS)-II [16], anthropological parameters (body weight, 
height, body mass index, blood pressure, and waist circum-
ference), laboratory blood tests, and risk evaluation of cer-
tain non-communicable diseases (cardiovascular disease, 
breast cancer, osteoporosis), respectively (supplementary 
file 1). The selection of the treatment option (CR or MHT) 
was based on the above-described routine assessment by the 
physician, a benefit–risk evaluation, and the patients wish at 
the time of consultation. For the final analysis, all patients 
treated with either Ze 450  (Cimifemin® forte = 13 mg dry 
extract,  Cimifemin® uno = 6.5 mg dry extract or  Climavita® 
forte = 13 mg dry extract) or any MHT (but not both) during 
the follow-up period and having at least one follow-up visit 
including blood tests were eligible. The study was approved 
by the cantonal ethics committee (Kantonale Ethik-kommis-
sion Bern (KEK) Switzerland No 2016-01179).
Data sources
Data from medical records were transferred to a REDCap 
(Research Electronic Data Capture) database. Genera-
tion, transmission, storage, and analysis of health-related 
personal data within this project were according to the cur-
rent Swiss legal requirements for data protection and were 
performed according to the Ordinance HRO Art. 5. This 
observational study is reported according to the STROBE 
statement (see www.strob e-state ment.org).
Statistical methods
Patients were grouped according to whether they were 
treated with Ze 450 or MHT during the follow-up period. 
Continuous and categorical variables are presented by 
group using median with lower and upper quartiles (lq, 
uq), and number and percentage of patients, respectively. 
Baseline characteristics between groups were compared 
using Wilcoxon rank-sum tests and Fisher’s exact tests for 
continuous and categorical variables, respectively. Linear 
mixed-effects regression models were used for the anal-
ysis of a change over time within and between groups. 
The endpoint values at baseline and each follow-up were 
used as dependent variable and the treatment group (i.e., 
MHT or Ze 450), the time, and the interaction of time and 
group as fixed explanatory variables. A random intercept 
was included for each patient to account for intra-patient 
correlations. The models were fitted with restricted maxi-
mum likelihood, the degrees of freedom were calculated 
using the Satterthwaite approximation and 95% confidence 
intervals (95% CI) based on the t distribution. Marginal 
effects for each group were calculated using Stata’s margin 
command and expressed as mean change per year with 
95% CI and a p value. The difference between groups (i.e., 
the interaction term of group and time) was expressed as 
mean difference per year (Ze 450 minus MHT) with 95% 
CI and a p value. For the main analysis, all patients in 
the full analysis set were included, regardless whether a 
baseline and a follow-up assessment were available for a 
specific endpoint. For a sensitivity analysis, only patients 
with a baseline and at least one follow-up measurement 
were included (referred to as complete case analysis). 
We used a multi-variable linear mixed-effects regression 
to adjust for confounding. All baseline variables with a 
p value < 0.2 in the baseline comparison and less than 
30% missingness in both groups were included as covari-
ates. An overall control of the type I error rate was not 
done because of the explorative nature of the study. The 
reported p values were not corrected for multiplicity and 
have to be interpreted accordingly. All analyses were done 
with Stata [StataCorp. Stata Statistical Software: Release 
14. StataCorp, College Station, TX: StataCorp LP., 2015.] 
or R [R Core Team. R: A Language and Environment for 
Statistical Computing. R Foundation for Statistical Com-
puting, Vienna, Austria, 2016. URL http://www.R-proje 
ct.org. ISBN 3-900051-07-0.].
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Results
Participants
Figure 1 displays the patient flow. Of 769 patients screened, 
174 were eligible for the final analysis. Of those, 32 were 
treated with Ze 450 and 142 with MHT, respectively. Cur-
rent systemic MHT regimens comprised mainly estro-
gen–progestogen combinations (n = 89; 63%), while the 
remainder received either estrogens only, progestogens only, 
estrogen–androgen combinations, or tibolone, respectively. 
Only few patients in the Ze 450 group (n = 3; 9%) but most 
in the MHT group (n = 103; 73%) had a history of MHT use. 
However, at first consultation few patients were using Ze 450 
(n = 8; 25%) or MHT (n = 49; 35%), respectively. All Black 
cohosh user had a Ze 450 product. Of those, the majority had 
a daily dosage of Ze 450 at 13 mg dry extract (n = 25; 78%; 
recommended dose 1 tablet daily).
Subjects’ characteristics at baseline
Table 1 presents subjects’ anthropological, reproductive, and 
lifestyle parameters at baseline. There was no significant 
intergroup difference but for reproductive stage (p = 0.038). 
The majority of women treated with Ze 450 were postmeno-
pausal (n = 24; 83%), while only one in two women treated 
with MHT fell into this category (n = 66; 55%). About one-
third of MHT-treated women were either premenopausal 
(n = 21; 17%) or in the early menopausal transition (n = 23; 
19%). In both groups, mean follow-up was 12 months (Ze 
450 lq, uq 12.0, 24.0; MHT lq, uq 12.0, 36.0; p = 0.91). 
There was a significant difference in the number of follow-up 
visits (p = 0.011). 88% (Ze 450) and 61% (MHT) of subjects 
had only one follow-up visit. A few women treated with Ze 
450 had two (n = 2; 6%), three (n = 1; 3%), or four (n = 1; 
3%) follow-up visits, compared to 41 (29%) with two, 12 
(8%) with three, and 3 (2%) with four follow-up visits in the 
MHT group.
Table 2 presents the type and intensity of menopausal 
symptoms at baseline, assessed by the questionnaire MRS-
II. In both groups, median intensity of overall menopausal 
symptoms (MRS-II total score) at baseline was moderate 
(defined as score 9–16) to severe (defined as score ≥ 17) 
(p = 0.46). When differentiating between menopausal symp-
tom subdomains, both groups suffered from moderate veg-
etative symptoms (defined as score 5–8) (p = 0.10) and mod-
erate (defined as score 2–3)-to-severe (defined as score ≥ 4) 
urogenital symptoms (p = 0.89), respectively. Psychological 
menopausal symptoms were moderate (defined as score 4–6) 
at baseline in both groups with women choosing MHT later 
on being slightly but significantly more affected than women 
choosing Ze 450 (p = 0.011).
Change of menopausal symptoms, body weight, 
and metabolic parameters over time
We did not find any evidence for a within-group change in 
body weight, carbohydrate metabolism (glucose, insulin, 
and HOMA-IR), and serum lipids (total cholesterol, LDL-
cholesterol, HDL-cholesterol, and triglycerides), neither in 
women treated with Ze 450 nor with MHT (Table 3). For 
MHT, we found a significant improvement over time of the 
MRS-II total score (− 0.99 [95% CI − 1.42, − 0.55] per year; 
p < 0.0001), MRS-II vegetative subscore (− 0.24 [95% CI 
− 0.45, − 0.03] per year; p = 0.023), MRS-II psychological 
subscore (− 0.48 [95% CI − 0.71, − 0.25]; p < 0.0001), and 
MRS-II urogenital subscore (− 0.28 [95% CI − 0.45, − 0.11]; 
p = 0.001). Similarly, treatment with Ze 450 significantly 
improved the MRS-II vegetative subscore (− 0.81 [95% CI 
− 1.57, − 0.04]; p = 0.039) and urogenital subscore (− 0.64 
[95% CI − 1.26, − 0.01]; p = 0.045) (Table 3). MRS-II total 
score had the same trend (− 1.43 [95% CI − 3.16, 0.30]; 
p = 0.11). Between-group comparisons did not reveal sig-
nificant differences for any endpoint (Table 3).
To adjust for potential confounding, we included baseline 
variables with a p value < 0.2 in the baseline comparisons 
and less than 30% missingness (diastolic blood pressure, age 
at menarche, reproductive stage, smoking status, MRS-II 
vegetative subscore, and MRS-II psychological subscore) 
in multi-variable models (Table 4). Results were similar as 
in the univariable models. For MHT, we found evidence for 
a change of the MRS-II total score (− 0.87 [95% CI − 1.26, 
− 0.48] per year; p < 0.0001), the psychological subscore 
(− 0.42 [95% CI − 0.60, − 0.24] per year; p < 0.0001), and 
Patients screened
N = 769
Excluded (N = 145)
- age <40 years (N = 138)
- age missing (N = 1)
- no baseline date (N = 6)
Patients eligible
N = 624
Excluded (N = 450
- not followed-up (N= 314
- missing treatment info (N = 22)
- received both treatments (N = 22)
- not treated (N = 60)
Patients analyzed
N = 174
Treated with Cimicifuga
N = 32
Treated with MHT
N = 142
Fig. 1  Patient flow from screening until final analysis
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the urogenital subscore (− 0.24 [95% CI − 0.42 to − 0.07] 
per year; p = 0.005). For Ze 450, we found some evidence 
for a change of the total score (− 1.82 [95% CI − 3.65, 
0.02]; p = 0.05) and the urogenital subscore (− 0.79 [95% 
CI − 1.60, 0.02]; p = 0.05). We did not find any evidence for 
a between-group difference. Furthermore, we did not find 
within or between-group changes for body weight and serum 
metabolic parameter (total cholesterol, LDL-cholesterol, 
HDL-cholesterol, triglycerides, fasting glucose, insulin, and 
HOMA-IR) (Table 4).
Discussion
This monocentric, retrospective, observational study 
found that (1) both the Black cohosh dry extract Ze 450 
and MHT markedly reduced menopausal symptoms over 
time without displaying significant intergroup differences 
with (2) MHT having a significant beneficial impact on 
psychological and urogenital symptom relief. Further-
more (3) in contrast to our expectations of weight gain 
Table 1  Subjects’ characteristics at baseline
N total number of observations, n number of non-missing observations
Parameter Ze 450 (N = 32) MHT (N = 142) p value
n Median [lq, uq] or n (%) n Median [lq, uq] or n (%)
Age (years) 32 53.0 [48.5, 55.0] 142 52.0 [47.0, 55.0] 0.93
Body mass index (kg/m2) 31 24.5 [22.7, 27.4] 136 24.1 [21.2, 28.6] 0.68
Waist circumference (cm) 26 85.0 [79.0, 102.0] 122 88.0 [79.0, 96.0] 0.79
Systolic blood pressure (mmHg) 31 120 [112, 135] 138 120 [112, 130] 0.50
Diastolic blood pressure (mmHg) 31 80.0 [75.0, 88.0] 138 80.0 [70.0, 84.0] 0.13
Age at menarche (years) 31 14.0 [13.0, 15.0] 134 13.0 [12.0, 15.0] 0.16
Cycle length (days) 9 28.0 [28.0, 29.0] 24 28.0 [26.5, 28.0] 0.36
Age at menopause (years) 18 49.5 [45.0, 53.0] 67 48.0 [42.0, 51.0] 0.14
Time since last menstruation (years) 29 2.40 [0.47, 10.54] 124 2.42 [0.28, 8.44] 0.75
Reproductive stage according to STRAW + 10 [15] 29 121 0.038
 Premenopause 1 (3%) 21 (17%)
 Early menopausal transition 2 (7%) 23 (19%)
 Late menopausal transition 2 (7%) 11 (9%)
 Postmenopause 24 (83%) 66 (55%)
Smoking 32 142 0.09
 Never 18 (56%) 102 (72%)
 Currently 8 (25%) 30 (21%)
 In the past 6 (19%) 10 (7%)
Alcohol 32 142 0.67
 Never 16 (50%) 59 (42%)
 Regularly 6 (19%) 27 (19%)
 From time to time 10 (31%) 56 (39%)
AGLA® 10-year risk for fatal and non-fatal coronary 
heart disease (%)
21 0.70 [0.50, 1.20] 89 0.40 [0.20, 1.20] 0.12
FRAX® 10-year risk for osteoporotic fractures (%) 29 5.70 [4.40, 7.00] 127 5.60 [4.10, 7.10] 0.68
GAIL® 5-year risk for breast cancer (%) 31 1.30 [1.20, 1.50] 137 1.40 [1.10, 1.90] 0.22
Table 2  Prevalence of 
menopausal symptoms at 
baseline, assessed by MRS-II
N total number of observations, n number of non-missing observations, Q question
MRS-II score Ze 450 (N = 32) MHT (N = 142) p value
n Median [lq, uq] n Median [lq, uq]
Total score (Q1–Q11) 25 16.0 [9.0, 20.0] 129 17.0 [11.0, 21.0] 0.46
Vegetative subscore (Q1, Q2, Q3, Q11) 26 8.00 [5.00, 10.00] 129 6.00 [4.00, 9.00] 0.10
Psychological subscore (Q4–Q7) 26 4.00 [2.00, 5.00] 129 5.00 [3.00, 9.00] 0.011
Urogenital subscore (Q8–Q10) 26 3.50 [2.00, 6.00] 129 4.00 [2.00, 6.00] 0.89
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during menopause [1, 2], we did not find any evidence for 
a change in body weight and metabolic parameters (serum 
lipids, carbohydrate metabolism) over time. However, 
uncertainty of the estimated effects was large. Finally, (4) 
potential confounders did not alter the results.
Clearly, this study has some limitations. The study 
was explorative and we tested many hypotheses without 
controlling the overall type I error rate—all results have to 
be interpreted accordingly. As this was a retrospective obser-
vational study, treatment indication, dosage, and duration 
were heterogenous. Sample size per group was small, the 
number of missing data was quite high, and we did not have 
an untreated control group. The power to detect differences 
between groups was small and not finding any does not 
Table 3  Change of menopausal symptoms, body weight, and metabolic parameters over time
N observa-
tions/
patients
Ze 450 MHT Difference (Ze 450-MHT)
Change per year (95% 
CI)
p value Change per year (95% 
CI)
p value Per year (95% CI) p value
Body weight (kg) 239/171 − 0.17 (− 1.15, 0.82) 0.74 0.46 (− 0.02, 0.94) 0.06 − 0.63 (− 1.72, 0.47) 0.26
Fasting glucose (mmol/l) 208/145 0.06 (− 0.11, 0.23) 0.47 0.00 (− 0.08, 0.08) 0.94 0.06 (− 0.13, 0.25) 0.53
Fasting insulin (mU/l) 140/114 0.51 (− 0.99, 2.00) 0.51 − 0.26 (− 0.95, 0.44) 0.47 0.76 (− 0.89, 2.41) 0.37
HOMA index 133/110 0.17 (− 0.23, 0.57) 0.41 − 0.09 (− 0.27, 0.10) 0.36 0.26 (− 0.19, 0.70) 0.26
Total cholesterol 
(mmol/l)
232/157 0.07 (− 0.06, 0.19) 0.29 0.02 (− 0.05, 0.08) 0.65 0.05 (− 0.09, 0.19) 0.47
HDL-cholesterol 
(mmol/l)
232/157 0.01 (− 0.06, 0.07) 0.84 0.01 (− 0.03, 0.04) 0.74 0.00 (− 0.08, 0.08) 0.98
LDL-cholesterol 
(mmol/l)
231/158 0.04 (− 0.08, 0.15) 0.55 − 0.01 (− 0.08, 0.05) 0.65 0.05 (− 0.08, 0.18) 0.46
Triglyceride (mmol/l) 233/157 − 0.04 (− 0.17, 0.09) 0.58 0.00 (− 0.07, 0.07) 0.94 − 0.04 (− 0.19, 0.11) 0.59
MRS-II Total score 282/158 − 1.43 (− 3.16, 0.30) 0.11 − 0.99 (− 1.42, − 0.55) < 0.0001 − 0.44 (− 2.23, 1.34) 0.63
MRS-II vegetative score 283/158 − 0.81 (− 1.57, − 0.04) 0.039 − 0.24 (− 0.45, − 0.03) 0.023 − 0.57 (− 1.36, 0.23) 0.16
MRS-II psychological 
score
283/158 0.28 (− 0.56, 1.13) 0.51 − 0.48 (− 0.71, − 0.25) < 0.0001 0.76 (− 0.11, 1.63) 0.09
MRS-II urogenital score 283/158 − 0.64 (− 1.26, − 0.01) 0.045 − 0.28 (− 0.45, − 0.11) 0.001 − 0.36 (− 1.00, 0.29) 0.28
Table 4  Change of body weight, metabolic parameters and menopausal symptoms over time after adjustment for baseline covariates (diastolic 
blood pressure, age at menarche, reproductive stage, smoking status, MRS-II vegetative subscore, and MRS-II psychological subscore)
Only the effects of MHT and Ze 450 are shown
N observa-
tions/
patients
Ze 450 MHT Difference (Ze 450−MHT)
Change per year (95% 
CI)
p value Change per year (95% 
CI)
p value Per year (95% CI) p value
Body weight (kg) 180/126 − 0.21 (− 1.23, 0.81) 0.69 0.35 (− 0.10, 0.79) 0.13 − 0.55 (− 1.67, 0.56) 0.33
Fasting glucose (mmol/l) 153/106 0.04 (− 0.18, 0.26) 0.72 − 0.00 (− 0.09, 0.09) 0.97 0.04 (− 0.19, 0.28) 0.73
Fasting insulin (mU/l) 105/85 1.12 (− 0.95, 3.20) 0.29 − 0.53 (− 1.37, 0.31) 0.21 1.66 (− 0.58, 3.89) 0.15
HOMA index 99/82 0.33 (− 0.24, 0.89) 0.26 − 0.13 (− 0.36, 0.10) 0.26 0.46 (− 0.15, 1.07) 0.14
Total cholesterol 
(mmol/l)
169/112 0.09 (− 0.04, 0.22) 0.17 0.00 (− 0.06, 0.07) 0.89 0.09 (− 0.06, 0.24) 0.25
HDL-cholesterol 
(mmol/l)
169/112 − 0.01 (− 0.08, 0.07) 0.84 − 0.00 (− 0.04, 0.04) 0.89 − 0.00 (− 0.09, 0.08) 0.91
LDL-cholesterol 
(mmol/l)
168/113 0.06 (− 0.07, 0.20) 0.34 − 0.01 (− 0.08, 0.05) 0.70 0.08 (− 0.07, 0.22) 0.30
Triglyceride (mmol/l) 169/112 0.01 (− 0.11, 0.13) 0.87 0.00 (− 0.06, 0.07) 0.94 0.01 (− 0.13, 0.15) 0.91
MRS-II Total score 231/126 − 1.82 (− 3.65, 0.02) 0.05 − 0.87 (− 1.26, − 0.48) <  0.0001 − 0.94 (− 2.82, 0.93) 0.32
MRS-II vegetative score 231/126 − 0.69 (− 1.50, 0.12) 0.10 − 0.16 (− 0.33, 0.01) 0.07 − 0.53 (− 1.36, 0.29) 0.21
MRS-II psychological 
score
231/126 − 0.14 (− 1.00, 0.72) 0.75 − 0.42 (− 0.60, − 0.24) < 0.0001 0.28 (− 0.59, 1.16) 0.52
MRS-II urogenital score 231/126 − 0.79 (− 1.60, 0.02) 0.05 − 0.24 (− 0.42, − 0.07) 0.005 − 0.55 (− 1.37, 0.28) 0.19
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provide evidence for the equality of the treatments. The pre-
specified power analysis showed that 150 and 850 patients 
treated with Ze 450 and MHT, respectively, would be neces-
sary to detect realistic effect sizes of 0.25 with a power of 
80%. The absence of an untreated control group makes it 
impossible to exclude a placebo effect, in particular since 
we only found effects on subjective endpoints (the MRS 
scores). We assumed linear effects of time on all outcomes. 
This assumption is unlikely to be true but seems reasonable 
over the rather short follow-up time. The small sample size 
did not allow us to study the effect of time in more detail. 
On the other hand, the strength of the study was its real-
life character when treatment initiation depends on multi-
ple factors and does not exclude anyone like in prospective 
randomized-controlled trials. These results can, therefore, 
be transferred into the daily life situation of gynecologists 
working in outpatient clinics and private practices.
Interestingly, serum vitamin D3 levels were significantly 
lower in Ze 450 than in MHT-treated women. According 
to national guidelines, mean serum vitamin D3 levels were 
below the recommended serum levels within the Black 
cohosh cohort but within the recommended range in MHT-
treated women (> 50 mmol/l) [17]. However, vitamin D 
supplementation has not been shown to have an impact on, 
e.g., glycemia or insulin resistance [18]. The assessment of 
vitamin D was incomplete (63% and 75% of the women had 
an assessment at baseline in Ze 450 and MHT group, respec-
tively) and we did not include it in the multi-variable model.
The observation of a beneficial impact of the Black cohosh 
dry extract Ze 450 on menopausal symptoms is shown in an 
RCT [19] and supports a previous systematic review showing 
a reduction of vasomotor symptoms if Black cohosh products 
approved by regulatory authorities were applied (in contrast 
to Black cohosh products regulated as food supplementation) 
[10]. At baseline, menopausal symptoms were moderate to 
severe in both cohorts and improved over time with the Black 
cohosh extract Ze 450 and MHT being comparably effec-
tive. Interestingly, women with psychological menopausal 
symptoms were more likely to choose MHT later on. This 
might be due to the significantly increased risk of depression 
during perimenopause [20] and the known positive impact 
of MHT on mood [8, 21]. However, due to the small sample 
size, we were not able to differentiate between different MHT 
formulations, dosages, and indications. As significantly more 
women treated with Ze 450 than MHT were postmenopau-
sal, we can only speculate that MHT was also prescribed for 
other indications than vasomotor symptom relief, e.g., for 
menstrual cycle regulation.
Both the menopausal transition and ageing have been 
shown to be accompanied by body weight increase and adverse 
changes in body composition and metabolic parameters [1, 2, 
4, 5]. A study showed that women with metabolic syndrome 
had a higher total score of MRS and a higher subscale score for 
somatic symptoms, such as hot flashes and sweating [22]. For 
most affected women, any treatment with little adverse effects 
that may slow down or even stop this progression would be 
welcomed. For MHT, beneficial effects on body weight, body 
composition, and metabolic parameters have been described 
before [6–8]. However, many menopausal women and physi-
cians are reluctant to use MHT due to the perceived risks, 
especially breast cancer risk [23]. Therefore, herbal medicinal 
products such as Black cohosh or phytoestrogen supplements 
have gained much attention in recent years. Just recently, a sys-
tematic review and meta-analysis reported a decrease in body 
weight with phytoestrogen supplementation in healthy post-
menopausal women, but body weight gain in postmenopausal 
women with preexisting metabolic disorders [24]. In the pre-
sent study, we did not observe a negative impact of Ze 450 on 
body weight gain and metabolic parameters in any subgroup. 
Yet, in general, women in our cohort were quite healthy. Thus, 
if a herbal product like Black cohosh dry extract Ze 450 had a 
stabilizing impact on body weight and metabolic parameters in 
menopausal women, the net benefit would outperform the rare 
potential, mostly short-term gastrointestinal, side effects. Our 
study in women supports previous findings showing a benefi-
cial effect of Ze 450 on AMPK activity in vitro and on meta-
bolic parameters in rats [14]. However, we can only speculate 
on the exact mechanism of action of Ze 450 in our study as we 
did not measure AMPK activity.
This is the first study in humans on the impact of Ze 450 
on body weight and metabolic parameters. Definitely, these 
first results need confirmation in bigger and prospective trials.
Conclusion
Both MHT and Black cohosh improved menopausal symp-
toms. Body weight and serum metabolic parameters did not 
change in MHT or Black cohosh-treated women.
Acknowledgements We would like to extend special acknowledge-
ments to Andrea Isler for data extraction. Max Zeller Söhne AG, 
Romanshorn, Switzerland, supported this work.
Author contributions FL: data collection and manuscript editing. 
NS: manuscript writing and editing, and project administration. ZC: 
project development, and manuscript writing and editing. BL: data 
management, data analysis, and manuscript writing and editing. SP: 
project development, investigation, methodology, manuscript writing, 
and supervision.
Data availability Data were not available as analysis for further publi-
cations is in preparation.
Compliance with ethical standards 
Conflict of interest This is an investigator-initiated monocentric, ret-
rospective, observational study. The study was supported by Max Zel-
Archives of Gynecology and Obstetrics 
1 3
ler Söhne AG, Romanshorn. Catherine Zahner and Sabine Nebel are 
employees of Max Zeller Söhne AG. The authors were autonomous in 
data analyses and study report and declare no conflict of interest.
Informed consent Informed consent is not available as data are used 
retrospectively which have been collected already and it is impossible 
or disproportionately difficult to obtain consent due to the high number 
of patients.
Ethical approval In addition, documented refusal is not available in 
any of the patient files (as per clinical trial protocol approved by the 
cantonal ethics committee No 2016-01179).
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Davis SR, Castelo-Branco C, Chedraui P, Lumsden MA, Nappi 
RE, Shah D, Villaseca P, Writing Group of the International Men-
opause Society for World Menopause D (2012) Understanding 
weight gain at menopause. Climacteric 15(5):419–429
 2. Kapoor E, Collazo-Clavell ML, Faubion SS (2017) Weight gain 
in women at midlife: a concise review of the pathophysiology and 
strategies for management. Mayo Clin Proc 92(10):1552–1558
 3. Pimenta F, Maroco J, Ramos C, Leal I (2014) Predictors of weight 
variation and weight gain in peri- and post-menopausal women. J 
Health Psychol 19(8):993–1002
 4. Karvonen-Gutierrez C, Kim C (2016) Association of mid-
life changes in body size, body composition and obesity status 
with the menopausal transition. Healthcare (Basel). https ://doi.
org/10.3390/healt hcare 40300 42
 5. Derby CA, Crawford SL, Pasternak RC, Sowers M, Sternfeld B, 
Matthews KA (2009) Lipid changes during the menopause transi-
tion in relation to age and weight: the Study of Women’s Health 
Across the Nation. Am J Epidemiol 169(11):1352–1361
 6. Armeni E, Lambrinoudaki I, Ceausu I, Depypere H, Mueck A, 
Perez-Lopez FR, Schouw YT, Senturk LM, Simoncini T, Ste-
venson JC, Stute P, Rees M (2016) Maintaining postreproductive 
health: a care pathway from the European Menopause and Andro-
pause Society (EMAS). Maturitas 89:63–72
 7. The NAMS 2017 Hormone Therapy Position Statement Advisory 
Panel (2017) The 2017 hormone therapy position statement of The 
North American Menopause Society. Menopause 24(7):728–753
 8. Baber RJ, Panay N, Fenton ATIWG (2016) 2016 IMS recom-
mendations on women’s midlife health and menopause hormone 
therapy. Climacteric 19(2):109–150
 9. The North American Menopause Society (2015) Nonhormonal 
management of menopause-associated vasomotor symptoms: 
2015 position statement of The North American Menopause 
Society. Menopause 22(11):1155–1174
 10. Beer AM, Osmers R, Schnitker J, Bai W, Mueck AO, Meden H 
(2013) Efficacy of black cohosh (Cimicifuga racemosa) medicines 
for treatment of menopausal symptoms—comments on major 
statements of the Cochrane Collaboration report 2012 “black 
cohosh (Cimicifuga spp.) for menopausal symptoms (review). 
Gynecol Endocrinol 29(12):1022–1025
 11. Oktem M, Eroglu D, Karahan HB, Taskintuna N, Kuscu E, 
Zeyneloglu HB (2007) Black cohosh and fluoxetine in the 
treatment of postmenopausal symptoms: a prospective, rand-
omized trial. Adv Ther 24(2):448–461
 12. Rhyu MR, Lu J, Webster DE, Fabricant DS, Farnsworth NR, 
Wang ZJ (2006) Black cohosh (Actaea racemosa, Cimicifuga 
racemosa) behaves as a mixed competitive ligand and partial 
agonist at the human mu opiate receptor. J Agric Food Chem 
54(26):9852–9857
 13. Burdette JE, Liu J, Chen SN, Fabricant DS, Piersen CE, Barker 
EL, Pezzuto JM, Mesecar A, Van Breemen RB, Farnsworth NR, 
Bolton JL (2003) Black cohosh acts as a mixed competitive ligand 
and partial agonist of the serotonin receptor. J Agric Food Chem 
51(19):5661–5670
 14. Moser C, Vickers SP, Brammer R, Cheetham SC, Drewe J 
(2014) Antidiabetic effects of the Cimicifuga racemosa extract 
Ze 450 in  vitro and in  vivo in ob/ob mice. Phytomedicine 
21(11):1382–1389
 15. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sher-
man S, Sluss PM, de Villiers TJ, Group SC (2012) Executive 
summary of the stages of reproductive aging workshop + 10: 
addressing the unfinished agenda of staging reproductive aging. 
Menopause 19(4):387–395
 16. Heinemann K, Ruebig A, Potthoff P, Schneider HP, Strelow F, 
Heinemann LA, Do MT (2004) The Menopause Rating Scale 
(MRS) scale: a methodological review. Health Quality Life Out-
comes 2:45
 17. Bischoff-Ferrari HA, Rosemann T, Grob D, Theiler R, Simmen 
H-P, Meyer O (2014) Vitamin-D-supplementation in der Praxis. 
Schweiz Med Forum 14(50):949–953
 18. Krul-Poel YH, Ter Wee MM, Lips P, Simsek S (2017) Manage-
ment of endocrine disease: the effect of vitamin D supplementa-
tion on glycaemic control in patients with type 2 diabetes mel-
litus: a systematic review and meta-analysis. Eur J Endocrinol 
176(1):R1–R14
 19. Schellenberg R, Saller R, Hess L, Melzer J, Zimmermann C, 
Drewe J, Zahner C (2012) Dose-dependent effects of the Cimicif-
uga racemosa extract Ze 450 in the treatment of climacteric 
complaints: a randomized, placebo-controlled study. Evid Based 
Complement Altern Med 2012:260301
 20. Freeman EW, Sammel MD, Lin H, Nelson DB (2006) Associations 
of hormones and menopausal status with depressed mood in women 
with no history of depression. Arch Gen Psychiatry 63(4):375–382
 21. MacQueen GM, Frey BN, Ismail Z, Jaworska N, Steiner M, 
Lieshout RJ, Kennedy SH, Lam RW, Milev RV, Parikh SV, Ravin-
dran AV, Group CDW (2016) Canadian Network for Mood and 
Anxiety Treatments (CANMAT) 2016 clinical guidelines for the 
management of adults with major depressive disorder: section 6. 
Special populations: youth, women, and the elderly. Can J Psy-
chiatry 61(9):588–603
 22. Lee SW, Jo HH, Kim MR, Kwon DJ, You YO, Kim JH (2012) 
Association between menopausal symptoms and metabolic 
syndrome in postmenopausal women. Arch Gynecol Obstet 
285(2):541–548
 23. Yeganeh L, Boyle J, Teede H, Vincent A (2017) Knowledge and 
attitudes of health professionals regarding menopausal hormone 
therapies. Climacteric 20(4):348–355
 24. Glisic M, Kastrati N, Musa J, Milic J, Asllanaj E, Portilla Fer-
nandez E, Nano J, Ochoa Rosales C, Amiri M, Kraja B, Bano 
A, Bramer WM, Roks AJM, Danser AHJ, Franco OH, Muka T 
(2018) Phytoestrogen supplementation and body composition in 
postmenopausal women: a systematic review and meta-analysis 
of randomized controlled trials. Maturitas 115:74–83
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
